Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI – Get Free Report) have received a consensus rating of “Buy” from the ...

Rani Therapeutics also announced its anticipation for a Phase 1 clinical trial in 2025 for RT-114, an oral GLP-1/GLP-2 dual agonist for obesity treatment, developed in partnership with ProGen ...

To get a sense of who is truly in control of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI), it is important to understand the ownership structure of the business. And the group that holds the ...

On February 5 th, Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) shared its preclinical readout from the RT-116 study demonstrating successful oral delivery of semaglutide using the RaniPill High ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on COMPASS Pathways (CMPS – Research Report) and ...

Rani Therapeutics has a 12-month low of $1.24 and a 12-month high of $8.75. Insider Activity at Rani Therapeutics In other news, insider Kate Mckinley bought 17,960 shares of the stock in a ...

Feb. 05, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of ...

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today ...